BDTX-4933-101 - A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Principal Investigator

Prof Mark Middleton

Contact us

Email: orh-tr.earlyphasenurses@nhs.net

IRAS number

1013168